| Document |
Document Title |
|
WO/2022/199045A1 |
Provided are a bicyclic heterocyclic FGFR4 inhibitor, a pharmaceutical composition and a preparation comprising same, and an application thereof. In particular, provided is a compound having a structure represented by formula (I), wherei...
|
|
WO/2022/201097A1 |
Provided herein are compounds and pharmaceutical compositions useful for treating diseases or disorders mediated by the TRPV1 receptor. The present invention also provides methods for treating ocular diseases or disorders by administerin...
|
|
WO/2022/199578A1 |
A class of fluorinated vinyl biphenyl derivatives and pharmaceutically acceptable salts thereof. Specifically disclosed is an application of compounds represented by formula (II) and pharmaceutically acceptable salts thereof in the prepa...
|
|
WO/2022/203332A1 |
The present invention provides a novel compound having a cyclohexyl-(alkyl or cycloalkyl-substituted)ethylene-amino-heteroaryl moiety or pharmaceutically acceptable salt thereof, a process for the preparation thereof, a pharmaceutical co...
|
|
WO/2022/202864A1 |
The present invention relates to: a compound, or a pharmacologically acceptable salt thereof, that has GLP-1 receptor agonist activity and that is useful as an agent for treating or preventing diseases involving the GLP-1 receptors; and ...
|
|
WO/2022/204299A1 |
Compounds having activity as inhibitors of LRRK2 kinase are provided. The compounds have Structure (I): or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein A, B, R1a, R1b, R2, and L are as defined herein. Meth...
|
|
WO/2022/199661A1 |
Provided is compound of Formula (Y) or Formula (A) or pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of GLP-1 receptor, a pharmaceutical composition comprising...
|
|
WO/2022/200785A1 |
There is provided pharmaceutical compounds of formula I, wherein R1, R2, R3, R4, R6, X, Y, Z, Y1, Y2, Y3 and Y4 have meanings given in the description, which compounds are useful in the treatment of autoimmune and/or fibrotic diseases, i...
|
|
WO/2022/199577A1 |
The present invention belongs to the technical field of pharmaceutical crystal chemistry, and relates in particular to anhydrous polymorphs of an androgen receptor antagonist, a preparation method therefor, and a use thereof. In particul...
|
|
WO/2022/199611A1 |
Provided is a heterocycle substituted ketone derivative, the structure of which is as shown in formula (I). Further provided are a pharmaceutically acceptable salt of the derivative, a stereoisomer thereof, a pharmaceutical composition a...
|
|
WO/2022/204227A1 |
The present disclosure relates to compounds that act as inhibitors of NLRP3 inflammasomes; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with inflammation and inflammaging, including h...
|
|
WO/2022/199458A1 |
Provided are a series of thiophene GLP-1 receptor agonist compounds, a preparation method therefor and the pharmaceutical use thereof. The compounds can be used for preparing drugs for treating or preventing GLP-1-mediated diseases and r...
|
|
WO/2022/199367A1 |
The present invention relates to the technical field of pharmaceutical chemistry, and provides a dithiocarbamate compound and a preparation method therefor, a pharmaceutical composition, and applications. The dithiocarbamate compound pro...
|
|
WO/2022/199589A1 |
A series of pyrimidine derivatives and the use thereof in the preparation of a drug for treating related diseases. Specifically disclosed are a compound as represented by formula (I) or a pharmaceutically acceptable salt thereof, and the...
|
|
WO/2022/199677A1 |
Compounds of general Formula S-1, S-2, S-3 and their pharmaceutically acceptable salts, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are synthesis, comp...
|
|
WO/2022/200208A1 |
Substituted pyrrolidin-2-ones, salts thereof and their use as herbicidally active substances The present invention relates to substituted pyrrolidin-2-ones of the general formula (I) or salts thereof, (I) where the radicals in the genera...
|
|
WO/2022/200576A1 |
The present invention relates to compounds of general formula (I) inhibiting DDR1 and DDR2. Particularly, the invention relates to compounds that are indoline derivatives, pharmaceutical compositions containing them and therapeutic use t...
|
|
WO/2022/199654A1 |
The present disclose includes, among other things, compounds that treat or lessen the severity of cancer, pharmaceutical compositions and methods of making and using the same.
|
|
WO/2022/199662A1 |
Provided are a compound represented by general formula (I), or a tautomer, mesomer, racemate, enantiomer, diastereomer or mixture thereof, a deuterium isotopic derivative, pharmaceutically acceptable hydrate, solvate, salt, or eutectic t...
|
|
WO/2022/197763A1 |
The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
|
|
WO/2022/193499A1 |
Provided herein are novel compounds (e.g., Formula I or II), pharmaceutical compositions, and methods of using related to Tyrosine kinase 2 (TYK2). The compounds herein are typically TYK2 inhibitors, which can be used for treating a vari...
|
|
WO/2022/194248A1 |
A CTLA-4 small molecule degradation agent and an application thereof. The CTLA-4 small molecule degradation agent comprises a compound having the structure represented by formula I or a pharmaceutically acceptable salt, an ester, a deute...
|
|
WO/2022/195497A1 |
The present disclosure relates to a process for the preparation of 4-piperidone HCl hydrate. The process of the present disclosure discloses the conversion of N-carbethoxy 4-piperidone to piperidone HCl hydrate in a comparatively high yi...
|
|
WO/2022/194269A1 |
A novel bifunctional compound (I) capable of degrading an EGFR, a pharmaceutical composition containing the compound, a preparation method, and a method for treating a cell proliferative disease, such as a cancer, by using the compound.
|
|
WO/2022/198112A1 |
Bifunctional compounds, of formula PTM-L-CLM, where the CLM is of formulae al-a4, the PTM f formula PTM-IA and L is a ligand. These compounds act on several diseases via agonism on LRRK2 and cereblon E3 ubiquitin ligase.
|
|
WO/2022/193806A1 |
The present invention relates to a method for asymmetric catalytic synthesis of nicotine, specifically to a method for preparing nicotine by five-step reaction by using 3-bromopyridine as a starting material, specifically comprising: 1) ...
|
|
WO/2022/198003A1 |
Described are 6-aryl isoindolin-1-ones as negative allosteric modulators of metabotropic glutamate receptor 2 (mGlu2), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating ...
|
|
WO/2022/194261A1 |
A compound as represented by formula (I), a stereoisomer and tautomer thereof or a pharmaceutically acceptable salt thereof, and the use thereof in the preparation of a drug for treating pain and a spinal cord injury.
|
|
WO/2022/194225A1 |
FXIa inhibitor compound impurities, and a preparation method and use therefor, comprising FXIa inhibitor compound impurity 1, impurity 2, and impurity 4. Also disclosed are a preparation method and use for the impurities. The provided FX...
|
|
WO/2022/194191A1 |
Provided are heterocyclics as inhibitors of KRAS G12D, in particular a compound of Formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising said compound that are useful for treatment of KRAS G...
|
|
WO/2022/194096A1 |
A compound represented by formula (I) or a stereoisomer, tautomer or pharmaceutical salt thereof, and use thereof in preparation of a medicament for preventing and/or treating estrogen receptor (ER)-related diseases or disorders.
|
|
WO/2022/197575A1 |
The present invention is directed to certain 2-aminoquinzaoline derivatives of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, R1, R2, and R3 are as defined herein, which are potent inhibitors of LRRK2 kinase a...
|
|
WO/2022/194252A1 |
Disclosed in the present invention are polymorphic forms of a compound and a preparation method therefor and an application thereof. A crystal form III of a compound A uses Cu-Kα radiation, and X-ray powder diffraction expressed at 2θ ...
|
|
WO/2022/197069A1 |
The present invention relates to a novel compound and a pharmaceutical composition containing same for treatment or prevention of transglutaminase-2-related diseases. Being capable of inhibiting transglutaminase-2 activity with significa...
|
|
WO/2022/197798A1 |
Provided herein are methods and compositions for the treatment of diseases of ACTH excess, such as Cushing's disease, ectopic ACTH syndrome, and congenital adrenal hyperplasia.
|
|
WO/2022/194259A1 |
It provides compounds of Formula I, compositions comprising the same, and methods of using the same, including use in treating various diseases and conditions, including those mediated by receptor-interacting protein 1 (RIP1) signaling.
|
|
WO/2022/195102A1 |
The present invention relates to a compound having the following formula (I) wherein: - R and R' are, independently from each other, H or (C1-C6)alkyl groups, or form together with the carbon atoms carrying them a (C6-C10)aryl group; - R...
|
|
WO/2022/194237A1 |
Provided are a quinoline derivative represented by general formula (I) and an application thereof in the preparation of an autoimmune drug.
|
|
WO/2022/194265A1 |
Provided are a quinazoline-based compound, a composition, and an application of the quinazoline-based compound, in particular, relating to a compound represented by formula (I), a stereoisomer thereof, a pharmaceutically acceptable salt ...
|
|
WO/2022/191681A1 |
The present invention provides a novel compound and an organic light emitting device comprising same.
|
|
WO/2022/188849A1 |
Provided herein are solid dispersions and pharmaceutical compositions of Compound 1. Also provided are methods of treating a disease or disorder such as a cancer or infectious disease that comprises administering to a subject in need the...
|
|
WO/2022/192428A1 |
The present disclosure provides GLP-1R agonists of Formula (I), and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
|
|
WO/2022/189810A1 |
This invention relates to compounds that can be used to treat viral infections. The compounds are papain-like protease (PLpro) inhibitors.
|
|
WO/2022/188889A1 |
The present invention provides a compound as a PARP7 inhibitor. Specifically, the present invention provides is a compound having a structure as represented by formula (I) below, or an optical isomer, pharmaceutically acceptable salt, pr...
|
|
WO/2022/191139A1 |
The purpose of the present invention is to provide a method for producing an intermediate for the production of a high-purity anthranilamide-based pesticide with high yield and high efficiency. Provided is a method for producing a comp...
|
|
WO/2022/188792A1 |
The present invention relates to a compound of formula (I), a pharmaceutical composition comprising same, a preparation method therefor, and a use thereof for preventing or treating tumor-related diseases or conditions.
|
|
WO/2022/189279A1 |
The present invention relates to crystalline forms of (4S)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(t
rifluoromethyl)-32H-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazo
la-2(1,2),7(1)-5 dibenzenaheptaphane-74-carboxamide which are...
|
|
WO/2022/189280A1 |
The present invention relates to solvates of (4S)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5- dioxo-14-(trifluoromcthyl)-32 H-6-aza-3(4,1)-pyridina-1(1)-[1.2.3]triazola-2(1,2),7(1)- dibenzenaheptaphane-74-carboxamide, to processes for t...
|
|
WO/2022/188758A1 |
The present invention relates to the field of biomedicine; provided are a quinoline compound salt or crystal form, a preparation method therefor, and an application thereof. The quinoline compound is as shown in formula (I), and the prov...
|
|
WO/2022/192745A1 |
Disclosed are compounds of Formula IIA, IIA-1, IIB, IIB-1, IIC and IIC-1: and pharmaceutical compositions and methods of use thereof These compounds inhibit Protein Arginine M-Methyl Transferase 5 (PRMT5) activity and are useful in metho...
|
